Orchestra Bio

Assess

Platforms

A life sciences R&D operations platform focused on AI-enabled workflows.

Why it's here

Placed in Assess: 1 article(s) of evidence from 1 source(s), led by funding news, with 1 in the last 30 days. Confidence 24%. Low accumulated evidence, so it defaults conservatively pending more signal.

Evidence (1)

7OpenAI Blog·10/20/2026funding
OpenAI Acquires Orchestra Bio
OpenAI is acquiring Orchestra Bio to expand AI-powered operations in life sciences research and development. The deal is aimed at helping biopharma teams speed up drug development and support the creation of new treatments.